U.S. Markets open in 33 mins.

Roche Holding AG (RHHBY)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
32.76+0.46 (+1.42%)
At close: 3:59PM EDT
People also watch
NVSSNYNSRGYAZNBAYRY
Full screen
Previous Close32.30
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume1,495,236
Market Cap215.88B
Beta0.51
PE Ratio (TTM)22.91
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.03 (3.14%)
Ex-Dividend Date2017-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters3 hours ago

    New Roche haemophilia drug prevents bleeds but questions remain

    Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year haemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire . Some analysts called Monday's data release convincing, with Jefferies saying it underpinned its $5 billion peak sales estimate for the medicine.

  • Reuters5 hours ago

    Roche says new haemophilia drug cuts bleed rate by 87 pct

    Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients who had developed resistance to standard treatment, compared with those who instead got bypassing agents, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year haemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire . In the late-stage study, 62.9 percent of patients receiving emicizumab experienced zero treated bleeds compared to 5.6 percent of those receiving so-called bypassing agents, Roche said.

  • How Dow's Merck Is Still Beating Bristol, Roche In Immuno-Oncology
    Investor's Business Daily5 days ago

    How Dow's Merck Is Still Beating Bristol, Roche In Immuno-Oncology

    Merck's Keytruda continued to gain share over immuno-oncology drugs from Bristol-Myers Squibb and Roche in May.